These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Bayer recently submitted an application to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for this third indication for darolutamide in addition ...

Bayer pharma chief sees no big acquisitions in near ... of some long-running mass tort litigation based on traditional product liability theories of toxic exposure, and potentially the rise ...

The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...

Berlin: Bayer has announced the submission of marketing authorization applications to the U.S. Food and Drug Administration ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

AB-1005 has received U.S. FDA Fast Track and UK Medicines and Healthcare products Regulatory Agency ... rigorous assessment and prioritization, Bayer Pharmaceuticals is now fully focused on ...

At the same time, the value of our pipeline is growing by accelerating breakthrough innovations," said Stefan Oelrich, Member of the Board of Management, Bayer AG, and President of Bayer’s ...